Primary paroxysmal dyskinesias are distinguished from episodic ataxias on clinical grounds as the latter involve episodes of incoordination and imbalance, but not dyskinesias. However, recent genetic findings have led to the two different clinical presentations being considered together. 1 They are characterized by episodic symptoms that usually begin in childhood or adolescence and tend to improve or even resolve later in life.
Most of the identified genetic mutations leading to paroxysmal disorders are related to membrane proteins expressed in neurons and are often linked with the regulation of cellular excitability. This review focuses on how new genetic findings have influenced the nosology of paroxysmal movement disorders and treatment strategies. A detailed review of each gene is available from GeneReviews www.ncbi.nlm.nih.gov/books/NBK1116/.
Structural damage to the central nervous system can manifest as a paroxysmal movement disorder in an exceedingly small proportion of patients. Nevertheless, because true primary paroxysmal movement disorders are rare, secondary paroxysmal movement disorders, which include demyelination, tumours, stroke, and neurodegenerative diseases, need to be clearly distinguished as part of the diagnostic process. Functional (psychogenic) paroxysmal movement disorders are not uncommon and should be promptly recognized and appropriately treated. Motor stereotypies, complex motor tics, developmental movement disorders (e.g. gratification phenomenon), and epileptic seizures need to be considered in the differential diagnosis, in particular in younger children.
PHENOTYPES
The clinical phenomenology of the primary paroxysmal dyskinesias was largely delineated and described in the second half of the twentieth century and has subsequently been embellished by advances in genetics particularly in the last decade.
Initial descriptions
Although descriptions of attacks of paroxysmal kinesigenic dyskinesia actually date as far back as 1892, 2 it was Mount and Reback 3 who described the first family with paroxysmal attacks of a movement disorder characterized by a combination of dystonia and choreoathetosis, which could be precipitated by fatigue, or alcohol, caffeine, or tobacco consumption. The terms 'paroxysmal choreoathetosis of Mount and Reback', 'familial paroxysmal choreoathethosis', and others were used until 1967 when Kertesz 4 very clearly described that some patients (but not all) could present with 'kinesigenic' triggers; attacks could be caused by sudden movement, like suddenly standing up from a chair, or suddenly starting to run after being still for a while. Various terms have been used over time to differentiate between the different forms, with a general agreement that 'kinesigenic' and 'nonkinesigenic' dyskinesias seemed to be different conditions, to which some applied the terms 'paroxysmal kinesigenic choreoathetosis' and 'paroxysmal dystonic choreoathetosis', both no longer in use.
Current classifications
In 1995 Dermirkiran and Jankovic 5 published the classification that is mostly used today, based on the analysis of 46 patients. In their study, they applied and revised the criteria previously used for classification: (1) type of triggers; (2) duration of attacks; (3) family history of such disorders; and (4) presence of previous or ongoing central nervous system injury. This series reflects usual findings in clinics elsewhere: secondary paroxysmal dyskinesias were more frequent than primary, and the frequency of nonkinesigenic dyskinesia was almost double that of kinesigenic. The authors classified paroxysmal dyskinesias into paroxysmal kinesigenic dyskinesia (PKD), paroxysmal nonkinesigenic dyskinesia (PNKD), paroxysmal exercise-induced dyskinesia (PED; which some call also 'exertion-induced'), and paroxysmal hypnogenic dyskinesia. Paroxysmal hypnogenic dyskinesias had been described in 1981 by Lugaresi and Cirignotta 6 as nocturnal attacks of dystonia during nonrapid eye movement sleep and without detectable epileptiform activity on concomitant electroencephalography. These were also called 'nocturnal hypnogenic paroxysmal dystonia' or 'nocturnal paroxysmal dystonia ' until 1990 , when the same group established the epileptic nature of such episodes in three patients. 7 Currently, in almost all patients, this condition is no longer considered a dyskinesia but a familial form of frontal lobe epilepsy in which frontal lobe discharges may not be easily detected with conventional electroencephalography, and it has been renamed nocturnal frontal lobe epilepsy which can be caused by mutations in several different genes (see the nocturnal frontal lobe epilepsy phenotypic series: http://omim.org/ phenotypicSeries/PS600513).
PKD
In 2004 Bruno et al. 8 reviewed clinical details of a multicentre retrospective cohort of 121 affected individuals from 73 families with PKD, and proposed the diagnostic criteria that is still largely used today to diagnose primary PKD: (1) identified kinesigenic trigger for the attacks; (2) short duration of attacks (<1min); (3) no loss of consciousness or pain during attacks; (4) exclusion of other organic diseases and normal neurological examination; (5) control of attacks with phenytoin or carbamazepine, if tried; (6) age at onset between 1 year and 20 years, if no family history of PKD. These criteria are summarized in Figure 1a . In their own cohort, 95 patients had what they called 'classic PKD' and fulfilled the criteria, while the remaining patients had atypical clinical features including 12 patients with infantile (<1y of age) onset of PKD and 14 patients in an 'outlier group' in which alternative diagnosis were considered including psychogenic movement disorder, nonkinesigenic, or paroxysmal exercise induced dyskinesia. They also highlighted that linkage analysis had associated a specific region of chromosome 16 with both PKD and infantile convulsion with choreoathetosis (ICCA) (Online Mendelian Inheritance in Man [OMIM] #602066, '#' indicating a phenotype entry in OMIM), suggesting that PKD, infantile convulsion with choreoathetosis, and familial infantile convulsions (also referred to as benign familial infantile epilepsy, benign familial infantile seizures, or benign familial infantile convulsions) could all be part of the phenotypic spectrum from mutations in the same gene.
PNKD
The phenotype of PNKD continues to evolve and presents with greater variability than PKD, and is frequently secondary to neurological conditions. After the discovery of the mutations on a gene causing classic familial PNKD in various families (see below), Bruno et al. 9 reviewed 49 patients from eight mutation-positive families, and 22 patients from six families who were mutation-negative. The criteria they suggested for the diagnosis of classic PNKD were: (1) hyperkinetic involuntary movement attacks with dystonia, chorea, or a combination of these, typically lasting 10 minutes to 1 hour, but up to 4 hours; (2) normal neurological examination between attacks and exclusion of secondary causes; (3) onset of attacks in infancy or early childhood; (4) precipitation of attacks by caffeine and alcohol consumption; and (5) family history of movement disorder meeting criteria 1 through 4. These are summarized in Figure 1b , which highlights that in addition to different triggers, PNKD attacks are longer than PKD attacks, less frequent, and respond to different medications.
PED
Paroxysmal exercise induced dyskinesia (PED) was first brought to attention in 1977 by Lance 10 who reported a family in which three affected members (grandfather, mother, and daughter) all suffered from episodes of dystonia with superimposed mild chorea, only after prolonged What the paper adds
• A growing number of genes have been associated with classic and newly described paroxysmal movement disorders.
• Paroxysmal movement disorders share common mechanisms and clinical features with other neurological paroxysmal phenomena including epilepsy and migraine.
exercise, but no other triggers such as sudden movement, or alcohol or tobacco consumption. He also noted that the duration of the episodes (mostly between 5min and 30min) were longer than PKD, but shorter than PNKD attacks. In one person who had tried medication, neither carbamazepine, phenytoin, nor clonazepam worked. It took another 7 years until Plant et al. 11 described the second family (mother and daughter) with what they termed 'Familial paroxysmal dystonia induced by exercise', and demonstrated that the dystonic movements could also be precipitated by prolonged sensory stimulation either with passive movement or vibration. Although the episodes were reported in the lower limbs in both families, Plant et al. could elicit PED in the upper limbs with prolonged exercise or sensory stimulation, and reasoned that the lower limbs predominance could be situational because they are more often used during prolonged exercise. There was family history of epilepsy. No formal diagnostic criteria were proposed, instead the clinical features described by Plant et al. 11 and Lance 10 are still used as guidelines to diagnose this rather rare condition; these are summarized in Figure 1c .
GENOTYPES AND EXPANDED PHENOTYPES
The genes underlying the main types of episodic ataxia were described in the 1990s. Episodic ataxia type 1 (OMIM #160120), which causes short episodes of ataxia (seconds to minutes) several times per week, and interictal myokymia, is associated with mutations in a gene that codes for one of the potassium channels, KCNA1 (K stands for potassium, CN for channel, and A1 is the type of potassium channel subunit, which can form homomeric or heteromeric channels).
In episodic ataxia type 2 (OMIM #108500), episodes are longer, lasting up to hours, less frequent, and interictal nystagmus (and not myokymia) is often seen. Episodic ataxia type 2 is associated with mutations in the gene for one of the subunits of the calcium channel, CACNA1A (CA stands for calcium, CN for channel, and A1A is a subunit of the channel, which is a heteromer composed of various different subunits coded by different genes). CACNA1A was also associated with other paroxysmal disorders including hemiplegic migraine (OMIM #141500), epilepsy (OMIM #617106 and others), benign paroxysmal torticollis of childhood, and paroxysmal tonic upward gaze, reflecting phenotypic pleiotropy (mutations in one single gene causing several distinct phenotypes). In addition, a different type of mutation of CACNA1A causing trinucleotide repeat also caused a non-paroxysmal disease: progressive cerebellar atrophy as in spinocerebellar atrophy type 6 (SCA6, OMIM #183086).
The gene underlying classic cases of PNKD was described in 2004 as MR-1 (myofibrillogenesis regulator 1, OMIM*609023, '*' indicating a gene entry in OMIM) later renamed PNKD, which is the currently accepted name. Other names used for this gene or locus include: MR1, MR-1, PDC, DYT8, FPD1, BRP17, PKND1, FKSG19, TAHCCP2, and KIPP1184. Unlike CACNA1A, this gene is not associated with significant phenotypic pleiotropy and in some cohorts was found to underlie the majority of classical familial cases of PNKD. Later in 2008 various cases of PED were shown to be caused by mutations in the gene GLUT-1 (glucose transporter type 1), now officially called SLC2A1 (OMIM*138140). SLC stands for solute carrier, and 2A1 for the family number 2, member number 1 in the family. The current nomenclature for genes coding non-active transporters is SLC. SLC2A1 (which many clinicians still continue to call GLUT-1) was described previously in association with infantile epilepsy with low cerebrospinal fluid glucose, initially described by De Vivo et al. in 1991. 12 Today it is apparent that although isolated PED caused by SLC2A1 mutations is rare, episodes of PED in sufferers from GLUT-1 deficiency syndrome are common, but often go unnoticed in the setting of epilepsy and other more severe findings. 13 Isolated dystonia after exercise (usually affecting only the lower limbs) has also been observed in carriers of mutations causing early-onset Parkinsonism (such as PAR-KIN, OMIM*602544) or dopa-responsive dystonia (such as GCH1, OMIM*602544), but are rather unusual initial presentations of these conditions.
The gene underlying most cases of PKD was the latest one to be identified and was described at a time when genomic technology had advanced significantly, therefore allowing for a very swift description of a vast array of disparate phenotypes, demonstrating impressive phenotypic pleiotropy. PRRT2 (OMIM*614386) which stands for proline-rich transmembrane protein 2, codes for a transmembrane protein whose function is relatively unknown, but seems to be involved in synaptic transmission. Between 2011 and 2013 it was associated not only with PKD, but also shown to be the cause for the majority of cases of benign infantile familial seizures (OMIM #605751) and infantile convulsions with paroxysmal choreoathetosis (infantile convulsion with choreoathetosis, OMIM #602066), a frequent cause of hemiplegic migraine, in addition to one sporadic case of benign paroxysmal torticollis of infancy, and a few cases of episodic ataxia (some with homozygous mutation and accompanying features including developmental delay or epilepsy). The odyssey of PRRT2 into one of the most notable examples of phenotypic pleiotropy has been chronicled in various review articles and commentaries.
14-18 Figure 2 compares the phenotypic pleiotropy seen in PRRT2 with that of CACNA1A, KCNA1 and SLC2A1.
IMPACT ON PATIENT MANAGEMENT
Given the significant phenotypic pleiotropy observed in genetic paroxysmal movement disorders, and the overlap with clinical spectrums associated with other genes, history taking must encompass not only one type of episode, but also any history of the various possible paroxysmal phenomena in the patient and family members. Paroxysmal phenomena in these overlapping syndromes include: paroxysmal weakness, paroxysmal ataxia, paroxysmal chorea, paroxysmal dystonia, paroxysmal myokymia, paroxysmal eye movement abnormalities, migraine, and epilepsy. Table I provides a summary of clinical information that might suggest a particular gene is involved.
The diagnosis of paroxysmal conditions is often hampered by the lack of findings on neurological examination. Therefore, history and when possible video recordings of paroxysmal events are often the most useful tool. It can also be useful to ask the patient to mimic their actual episodes. Videos may be very useful but also have many caveats. Whenever possible they should be obtained with appropriate settings (frame, angle, lighting, duration, screen resolution, etc.) and the largest number of episodes possible. This can help differentiate between dyskinesias (dystonia and chorea) and ataxia, although gait ataxia can only be seen if the patient is filmed while walking, and ataxic uncoordinated movements in children can be confused with dyskinesias. Older children will report dizziness and vertigo, but smaller children may not be able to. Both episodic ataxias and paroxysmal dyskinesias tend to start in childhood or teenage years, rendering the initial diagnosis challenging.
Myokymia may be difficult to document and sometimes to interpret, but is a useful finding. It is a hallmark of episodic ataxia type 1 caused by KCNA1 mutations, and some family members may present with isolated myokymia. Familial dyskinesia with facial myokymia (OMIM #606703) is caused by mutations on the ADCY5 gene (OMIM*600293) and presents with facial movements now believed to represent facial dyskinesia (chorea) or facial myoclonus, and not true myokymia.
19 ADCY5 mutations present with a broad phenotypic spectrum and can initially manifest with paroxysmal dyskinesias (often sleep-related), making for an important differential diagnosis. 20 It is paramount to differentiate between episodes of positive symptoms (like dystonia or chorea) from negative symptoms. In particular paroxysmal hemiplegia, which is seen in hemiplegic migraine and in alternating hemiplegia of childhood (OMIM #104290); both conditions which show clinical and genetic overlap with paroxysmal dyskinesia. Mutations in PRRT2, the main known cause of classic PKD, can also cause hemiplegic migraine, and this condition may coexist in families or individuals. Mutations in ATP1A3 (OMIM*182350), the causative gene for alternating hemiplegia of childhood, are associated with a broad spectrum of phenotypic manifestation including episodes of hemiplegia and hemidystonia (isolated or combined), in addition to other features like developmental delay or loss of milestones. ATP1A3 mutations also cause rapid-onset dystonia Parkinsonism (previously called DYT12, OMIM #128235), cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (OMIM #601338). Although rapid-onset dystonia Parkinsonism and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss themselves do not manifest with paroxysmal dystonia, there is a growing notion that ATP1A3 mutations cause various intermediate phenotypes with clinical overlap. 21, 22 Although genetic testing is advisable, it is not always necessary for the treatment of patients. But it can help define the prognosis and aid in reproductive counselling, which is particularly important for conditions which carry greater disability like ATP1A3 phenotypes that can be inherited or are often caused by de-novo mutations, in which case they bear low recurrence risk except when there is underlying germline mosaicism. Figure 3 shows how phenotypic spectrums for various paroxysmal movement disorders overlap with migraine and epilepsy. As sequential testing for multiple genes is usually more expensive than a gene panel, most experts now recommend that either gene panel or exome sequencing might be preferable when there is not a very strong suspicion for a single gene. Gene panels are usually designed by different labs based on a central phenotype (like 'dystonia', 'chorea', 'paroxysmal movement disorder', etc.) while exome sequence will look at sequencing changes in the exons of roughly 20 000 genes. The main advantage of the panels over exome sequencing is that many include coverage for exon-level deletions or duplications, which do not alter sequence, and are not detected by standard sequencing techniques. Therefore, knowledge of the phenotypes, genotypes, and techniques is necessary before requesting the test, and when necessary the opinion of a specialist in neurogenetics or movement disorders is of great value.
Treatment for paroxysmal movement disorders remains mostly unchanged and, with the exception of a randomized controlled trial for 4-aminopyridine in episodic ataxia type 2, 23 all options are based on observational studies, expert consensus, or anecdotal evidence, and are mainly directed at the phenotype and not genotype. There is emerging evidence that triheptanoin might be useful in SLC2A1-related PED. 24 However, because a therapeutic trial with any of the available options (acetazolamide, antiepileptic drugs, benzodiazepines, levodopa, ketogenic diet, and potentially triheptanoin) is unlikely to support a specific diagnosis in patients with PED, diagnosis usually requires additional testing including cerebrospinal fluid glucose and neurotransmitters, erythrocyte glucose uptake, erythrocyte GLUT-1 expression, or testing for SLC2A1 mutations. 25 This is likely because of a combination of the rarity of these conditions and the fact that effective treatments were described before the era of genomics; PKD responds to between the main phenotypes and guide management without need for genetic diagnosis. Age at onset for almost all paroxysmal conditions associated with these genes is during infancy (benign paroxysmal torticollis, infantile convulsions, epileptic encephalopathy) or childhood/adolescence (episodic ataxias, paroxysmal kinesigenic dyskinesia), but they may occasionally start in adult life (paroxysmal exercise induced dyskinesia, epilepsy, progressive ataxia). AE, with or without. low dose carbamazepine (or phenytoin), PNKD often responds to benzodiazepines, and PED tends to respond poorly to medication, although benzodiazepines, levodopa, acetazolamide, antiepileptic drugs, and even ketogenic diet can be tried depending on severity.
1 A few cases of good response to deep brain stimulation have been reported in refractory severe PNKD 26, 27 and also on life-threatening exacerbations of dyskinesias in patients carrying mutations in GNAO1.
28 GNAO1 mutations have recently been described as a cause of early life movement disorder with or without epileptic encephalopathy, often wrongly labelled as 'dyskinetic cerebral palsy' with episodic 'dyskinetic storms' with poor response to oral medications. Acetazolamide, a carbonic anhydrase inhibitor which was initially used for epilepsy as an alternative to the ketogenic diet, remains the standard treatment for episodic ataxia type 2, in addition to flunarizine or 4-aminopyridine. Episodic ataxia type 1 responds to carbamazepine, valproic acid, and acetazolamide, but the response to acetazolamide in episodic ataxia type 1 is not as dramatic as in episodic ataxia type 2.
1,29 Therefore, although genetic testing might be useful for various different reasons, it is not necessary initially to target pharmacotherapy in patients with classic phenotypes.
CONCLUSION
Although genetics has so far had relatively little impact on the treatment of primary paroxysmal movement disorders, it has played a significant part in changing our understanding of the likely mechanisms involved in their causation. It is hoped that as a greater understanding of the chemical processes involved in the mediation of this fascinating group evolves, more specific and efficacious therapies can be developed.
RESUMEN FENOTIPOS, GENOTIPOS, Y EL MANEJO DE TRASTORNOS DE MOVIMIENTOS PAROX ISTICOS
Como consecuencias de la revoluci on gen omica, en los ultimos años se han presentado un gran n umero de publicaciones describiendo los trastornos de movimientos parox ısticos, arrojando luz sobre su patolog ıa molecular. Los estudios de genes rutinarios no son necesarios para la guiar el tratamiento para la forma t ıpica de disquinesia quinesig enica parox ıstica (DQP), disquinesia noquinesig enica parox ıstica (DNQP), y ataxia epis odica tipo 1 o 2. Sin embargo, puede ser de ayuda para el manejo de casos at ıpicos o complejos, especialmente para consejo gen etico, estrategias de tratamiento, y el ofrecimiento de diagn ostico gen etico pre implante. Las drogas anticonvulsivantes contin uan siendo el tratamiento de elecci on para DQP y ataxia epis odica tipo 1, las benzodiacepinas son utiles con frecuencia para DNQP, y la ataxia epis odica tipo 2 se beneficia con acetazolamida independientemente de la etiolog ıa gen etica.
RESUMO FEN OTIPOS, GEN OTIPOS, E O MANEJO DE DESORDENS MOTORAS PAROX ISTICAS
Como consequência da revoluc ßão genômica, um grande n umero de publicac ßões descrevendo desordens motoras parox ısticas tem sido publicado nos ultimos anos, esclarecendo sua patologia molecular. O teste gen etico de rotina não e necess ario para guiar o tratamento de formas t ıpicas de discinesia parox ıstica cinesigênica (DPC), discinesia parox ıstica não-cinesigênica (DPNC), e ataxia epis odica tipo 1 ou 2. Pode, no entanto, ser util no manejo de casos at ıpicos ou complexos, especialmente para aconselhamento gen etico, estrat egias de tratamento, e oferta de diagn ostico gen etico pr e-implantac ßão. Drogas anti-epil epticas permanecem como o tratamento de escolha da DPC e ataxia epis odica tipo 1, benzodiazep ınicos são frequentemente uteis para DPNC, e a ataxia epis odica tipo 2 se beneficia de acetazolamida independente da etiologia gen etica.
